Sign cancer research agreement
German biotechnology firm Kinaxo Biotechnologies and Daiichi Sankyo Company will work together in cancer research.
The two companies have agreed that Daiichi Sankyo will employ Kinaxo’s technology to support the development of the Japanese pharmaceutical firm’s targeted cancer drugs. Kinaxo will apply its chemical proteomics technologies Cellular Target Profiling and KinAffinity, as well as its phosphoproteomics technology PhosphoScout, within various research programmes pursued at Daiichi Sankyo.
Financial details were not revealed.
Cellular Target Profiling and KinAffinity use a combination of proprietary chemical proteomics and quantitative mass spectrometry technologies to identify a small molecule’s native cellular targets from biological samples.
PhosphoScout is a quantitative phosphoproteomics service tailored to dissect cellular signal transduction pathways and their response to drug treatment. It is applicable to both small molecules and antibodies.
Axel Ullrich, director at the Max Planck Institute for Biochemistry in Martinsried and Kinaxo board member, said: ‘Kinaxo has established a unique technology platform that allows comprehensive analysis of cancer signal transduction processes and their response to drug treatment. I am convinced that these innovative technologies will significantly contribute to the development of tomorrow’s cancer therapeutics.’